Inflammatory breast cancer: a review
The natural history of inflammatory breast cancer and the recent advances in its management were reviewed. The English medical literature from 1924 to 1990 was reviewed using the Cancerline and Medline retrieval systems, and through a manual review of bibliographies of identified articles. The major...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 1992-06, Vol.10 (6), p.1014-1024 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1024 |
|---|---|
| container_issue | 6 |
| container_start_page | 1014 |
| container_title | Journal of clinical oncology |
| container_volume | 10 |
| creator | JAIYESIMI, IA BUZDAR, AU HORTOBAGYI, G |
| description | The natural history of inflammatory breast cancer and the recent advances in its management were reviewed.
The English medical literature from 1924 to 1990 was reviewed using the Cancerline and Medline retrieval systems, and through a manual review of bibliographies of identified articles.
The majority of patients with inflammatory breast cancer treated only with local therapies died 18 to 24 months after diagnosis. A combined modality approach with chemotherapy, surgery, and radiation therapy has improved disease-free and overall survival rates for inflammatory breast cancer. Approximately 35% to 55% of patients treated with combined modality regimens remain disease-free and alive at 5 years.
Induction combination chemotherapy administered with radiation therapy, mastectomy, both, or with additional chemotherapy favorably alters the natural history of inflammatory breast cancer. New drug combinations and high-dose chemotherapy with autologous bone marrow support are being evaluated to improve further patient survival. |
| doi_str_mv | 10.1200/JCO.1992.10.6.1014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_A1992HW16400022CitationCount</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72954147</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-25c9dfd036913c18606fc2f80bba21d99ba4c6a8e56bb117964db2405fa7e0c23</originalsourceid><addsrcrecordid>eNqNkM1KAzEURoMotVZfQBC6KG5kapKZZDLuyqC2UuhG0V1IMolNmZ-aTC19ezO0tFs3Cdx77pfcA8AtgmOEIXx8yxdjlGV4HAo0HCg5A31EcBqlKSHnoA_TGEeIxV-X4Mr7FQwEi0kP9BBhLKa0D0az2pSiqkTbuN1QOi18O1SiVto9DcXQ6V-rt9fgwojS65vDPQAfL8_v-TSaL15n-WQeqZiwNsJEZYUpYEwzFCvEKKRGYcOglAKjIsukSBQVTBMqJUJpRpNC4gQSI1INFY4H4H6fu3bNz0b7llfWK12WotbNxvMUZyRBSRpAvAeVa7x32vC1s5VwO44g79TwoIZ3aroC5Z2aMHR3SN_IShenkb2L0B8d-sIrURoXLFh_xAihFNEu5mGPbbVsjFdWB1lHatI9Ov0MIIQQdyux_9O5bUVrmzpvNnV7srG038utdZr7SpRl-D3mK9WcFvsDkpiYZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72954147</pqid></control><display><type>article</type><title>Inflammatory breast cancer: a review</title><source>Web of Science - Science Citation Index Expanded - 1992<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Journals@Ovid Complete</source><creator>JAIYESIMI, IA ; BUZDAR, AU ; HORTOBAGYI, G</creator><creatorcontrib>JAIYESIMI, IA ; BUZDAR, AU ; HORTOBAGYI, G</creatorcontrib><description>The natural history of inflammatory breast cancer and the recent advances in its management were reviewed.
The English medical literature from 1924 to 1990 was reviewed using the Cancerline and Medline retrieval systems, and through a manual review of bibliographies of identified articles.
The majority of patients with inflammatory breast cancer treated only with local therapies died 18 to 24 months after diagnosis. A combined modality approach with chemotherapy, surgery, and radiation therapy has improved disease-free and overall survival rates for inflammatory breast cancer. Approximately 35% to 55% of patients treated with combined modality regimens remain disease-free and alive at 5 years.
Induction combination chemotherapy administered with radiation therapy, mastectomy, both, or with additional chemotherapy favorably alters the natural history of inflammatory breast cancer. New drug combinations and high-dose chemotherapy with autologous bone marrow support are being evaluated to improve further patient survival.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.1992.10.6.1014</identifier><identifier>PMID: 1588366</identifier><language>eng</language><publisher>ALEXANDRIA: American Society of Clinical Oncology</publisher><subject>Biological and medical sciences ; Breast Neoplasms - diagnosis ; Breast Neoplasms - mortality ; Breast Neoplasms - therapy ; Carcinoma - diagnosis ; Carcinoma - mortality ; Carcinoma - therapy ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Life Sciences & Biomedicine ; Mammary gland diseases ; Medical sciences ; Oncology ; Science & Technology ; Tumors</subject><ispartof>Journal of clinical oncology, 1992-06, Vol.10 (6), p.1014-1024</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>264</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wosA1992HW16400022</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c358t-25c9dfd036913c18606fc2f80bba21d99ba4c6a8e56bb117964db2405fa7e0c23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,3731,27199,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5566164$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1588366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JAIYESIMI, IA</creatorcontrib><creatorcontrib>BUZDAR, AU</creatorcontrib><creatorcontrib>HORTOBAGYI, G</creatorcontrib><title>Inflammatory breast cancer: a review</title><title>Journal of clinical oncology</title><addtitle>J CLIN ONCOL</addtitle><addtitle>J Clin Oncol</addtitle><description>The natural history of inflammatory breast cancer and the recent advances in its management were reviewed.
The English medical literature from 1924 to 1990 was reviewed using the Cancerline and Medline retrieval systems, and through a manual review of bibliographies of identified articles.
The majority of patients with inflammatory breast cancer treated only with local therapies died 18 to 24 months after diagnosis. A combined modality approach with chemotherapy, surgery, and radiation therapy has improved disease-free and overall survival rates for inflammatory breast cancer. Approximately 35% to 55% of patients treated with combined modality regimens remain disease-free and alive at 5 years.
Induction combination chemotherapy administered with radiation therapy, mastectomy, both, or with additional chemotherapy favorably alters the natural history of inflammatory breast cancer. New drug combinations and high-dose chemotherapy with autologous bone marrow support are being evaluated to improve further patient survival.</description><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - therapy</subject><subject>Carcinoma - diagnosis</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - therapy</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Oncology</subject><subject>Science & Technology</subject><subject>Tumors</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EZCTM</sourceid><sourceid>EIF</sourceid><recordid>eNqNkM1KAzEURoMotVZfQBC6KG5kapKZZDLuyqC2UuhG0V1IMolNmZ-aTC19ezO0tFs3Cdx77pfcA8AtgmOEIXx8yxdjlGV4HAo0HCg5A31EcBqlKSHnoA_TGEeIxV-X4Mr7FQwEi0kP9BBhLKa0D0az2pSiqkTbuN1QOi18O1SiVto9DcXQ6V-rt9fgwojS65vDPQAfL8_v-TSaL15n-WQeqZiwNsJEZYUpYEwzFCvEKKRGYcOglAKjIsukSBQVTBMqJUJpRpNC4gQSI1INFY4H4H6fu3bNz0b7llfWK12WotbNxvMUZyRBSRpAvAeVa7x32vC1s5VwO44g79TwoIZ3aroC5Z2aMHR3SN_IShenkb2L0B8d-sIrURoXLFh_xAihFNEu5mGPbbVsjFdWB1lHatI9Ov0MIIQQdyux_9O5bUVrmzpvNnV7srG038utdZr7SpRl-D3mK9WcFvsDkpiYZQ</recordid><startdate>19920601</startdate><enddate>19920601</enddate><creator>JAIYESIMI, IA</creator><creator>BUZDAR, AU</creator><creator>HORTOBAGYI, G</creator><general>American Society of Clinical Oncology</general><general>Amer Soc Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>BLEPL</scope><scope>DTL</scope><scope>EZCTM</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920601</creationdate><title>Inflammatory breast cancer: a review</title><author>JAIYESIMI, IA ; BUZDAR, AU ; HORTOBAGYI, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-25c9dfd036913c18606fc2f80bba21d99ba4c6a8e56bb117964db2405fa7e0c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - therapy</topic><topic>Carcinoma - diagnosis</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - therapy</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Oncology</topic><topic>Science & Technology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JAIYESIMI, IA</creatorcontrib><creatorcontrib>BUZDAR, AU</creatorcontrib><creatorcontrib>HORTOBAGYI, G</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 1992</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JAIYESIMI, IA</au><au>BUZDAR, AU</au><au>HORTOBAGYI, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inflammatory breast cancer: a review</atitle><jtitle>Journal of clinical oncology</jtitle><stitle>J CLIN ONCOL</stitle><addtitle>J Clin Oncol</addtitle><date>1992-06-01</date><risdate>1992</risdate><volume>10</volume><issue>6</issue><spage>1014</spage><epage>1024</epage><pages>1014-1024</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>The natural history of inflammatory breast cancer and the recent advances in its management were reviewed.
The English medical literature from 1924 to 1990 was reviewed using the Cancerline and Medline retrieval systems, and through a manual review of bibliographies of identified articles.
The majority of patients with inflammatory breast cancer treated only with local therapies died 18 to 24 months after diagnosis. A combined modality approach with chemotherapy, surgery, and radiation therapy has improved disease-free and overall survival rates for inflammatory breast cancer. Approximately 35% to 55% of patients treated with combined modality regimens remain disease-free and alive at 5 years.
Induction combination chemotherapy administered with radiation therapy, mastectomy, both, or with additional chemotherapy favorably alters the natural history of inflammatory breast cancer. New drug combinations and high-dose chemotherapy with autologous bone marrow support are being evaluated to improve further patient survival.</abstract><cop>ALEXANDRIA</cop><pub>American Society of Clinical Oncology</pub><pmid>1588366</pmid><doi>10.1200/JCO.1992.10.6.1014</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 1992-06, Vol.10 (6), p.1014-1024 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_webofscience_primary_A1992HW16400022CitationCount |
| source | Web of Science - Science Citation Index Expanded - 1992<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; MEDLINE; American Society of Clinical Oncology Online Journals; Journals@Ovid Complete |
| subjects | Biological and medical sciences Breast Neoplasms - diagnosis Breast Neoplasms - mortality Breast Neoplasms - therapy Carcinoma - diagnosis Carcinoma - mortality Carcinoma - therapy Female Gynecology. Andrology. Obstetrics Humans Life Sciences & Biomedicine Mammary gland diseases Medical sciences Oncology Science & Technology Tumors |
| title | Inflammatory breast cancer: a review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T05%3A35%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inflammatory%20breast%20cancer:%20a%20review&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=JAIYESIMI,%20IA&rft.date=1992-06-01&rft.volume=10&rft.issue=6&rft.spage=1014&rft.epage=1024&rft.pages=1014-1024&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.1992.10.6.1014&rft_dat=%3Cproquest_webof%3E72954147%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72954147&rft_id=info:pmid/1588366&rfr_iscdi=true |